key: cord-0733569-85ajqqxv
authors: Hajra, Adrija; Bandyopadhyay, Dhrubajyoti
title: COVID-19 and ACEI/ARB: NOT ASSOCIATED?
date: 2020-05-16
journal: Am J Hypertens
DOI: 10.1093/ajh/hpaa076
sha: 276f67626718f83706fd70c5b007506eb72be535
doc_id: 733569
cord_uid: 85ajqqxv

nan

A c c e p t e d M a n u s c r i p t Angiotensin receptor blockers (ARBs) have been shown to increase the levels of ACE2 in animal models of heart diseases. Angiotensin-converting enzyme inhibitors (ACEI) also increases the ACE2 level as it decreases the angiotensin II level, the substrate of the ACE2 enzyme. (2) . So, the concern is rising on whether the use of ACEI or ARB can increase the susceptibility of COVID-19 infection and the chance of lung injury secondary to increased Use of recombinant ACE2 could be a therapeutic approach in COVID-19 affected patients. It may reduce the viral load by binding circulating SARS-CoV-2 viral particles and reduce the potential attachment to tissue ACE2. (1) The use of this drug with ACEI/ARB is also another field to be explored. We all know the COVID-19 is a new threat for all health care providers, but we would like to request the authors to highlight the future of these widely used antihypertensives in the setting of this newly emerging infection.

Hypertension and COVID-19

Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19

Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China

Drug Therapy, and Mortality in Covid-19

A c c e p t e d M a n u s c r i p t